Abstract: Embodiments of the present invention provide a pharmaceutical intervention in the neonatal pig that inhibits and delays development and activation of the HPG axis, growth of the boar testis and inhibits testicular production of testosterone and androstenone, which prevents the development of aggressive behavior in the maturing boars and the presence of boar taint in the meat. The invention comprises treatment with a combination of an androgen and an estrogen in the newborn male piglet using extended drug delivery methods, with a defined duration of no more than 12 weeks, for the purpose of inhibiting the production of testosterone and androstenone and the accumulation of the boar taint-inducing molecules androstenone and skatole in the fat.

Abstract: A hybrid display may include different display portions with different resolutions. The high resolution display portion may be positioned in a main viewing area for the viewer whereas the low resolution display portion may be positioned in a peripheral viewing area. The high resolution display portion may have a silicon backplane. The low resolution display portion may have a different type of backplane such as a thin-film transistor backplane. The different display portions may optionally share a common organic light-emitting diode layer such that light is emitted from the same plane across both display portions. The high resolution display portion may emit light through a transparent window in the low resolution display portion. A high resolution display may also be formed by separately forming a frontplane and a backplane. Conductive attachment structures such as indium bumps may be used to mechanically and electrically connect the backplane to the frontplane.

Abstract: The invention provides isoform-selective anti-TGF? antibodies and methods of using the same. In particular, isoform-selective anti-TGF?2, anti-TGF?3, and anti-TGF?2/3 monoclonal antibodies are provided, e.g., for the treatment of fibrosis and other TGF?-related disorders.

Abstract: An acoustic liner is provided. The acoustic liner includes a face sheet, a back sheet spaced from the face sheet, and a core layer defining a cellular structure disposed between the face sheet and the back sheet. The core layer includes a plurality of first resonant cells coupled to the back sheet. Each of the first resonant cells includes a first cell wall coupled to the back sheet along a first cell wall base edge, the first cell wall extending from the back sheet toward the face sheet, the first cell wall further coupled to the face sheet along a first cell wall top edge, wherein the first cell wall of each of the first resonant cells comprises a surface extension that extends from a surface of the first cell wall.

Abstract: The present disclosure relates to a method for controlling the illumination of an occupant compartment of a motor vehicle with multiple illumination devices, wherein a region of the occupant compartment assigned to the respective illumination device can in each case be illuminated by means of the illumination devices, wherein at least one light-specific parameter assigned to at least one of the regions or at least one item of illumination information from which the light-specific parameter is derived is specified by the user, wherein a variable characteristic of the light generated by the illumination device in the region depends on the respectively assigned light-specific parameter.

Abstract: Embodiments of the present invention provide a pharmaceutical intervention in the neonatal pig that inhibits and delays development and activation of the HPG axis, growth of the boar testis and inhibits testicular production of testosterone and androstenone, which prevents the development of aggressive behavior in the maturing boars and the presence of boar taint in the meat. The invention comprises treatment with a combination of an androgen and an estrogen in the newborn male piglet using extended drug delivery methods, with a defined duration of no more than 12 weeks, for the purpose of inhibiting the production of testosterone and androstenone and the accumulation of the boar taint-inducing molecules androstenone and skatole in the fat.

Abstract: Embodiments of the present invention provide a pharmaceutical intervention in the neonatal pig that inhibits and delays development and activation of the HPG axis, growth of the boar testis and inhibits testicular production of testosterone and androstenone, which prevents the development of aggressive behavior in the maturing boars and the presence of boar taint in the meat. The invention comprises treatment with a combination of an androgen and an estrogen in the newborn male piglet using extended drug delivery methods, with a defined duration of no more than 12 weeks, for the purpose of inhibiting the production of testosterone and androstenone and the accumulation of the boar taint-inducing molecules androstenone and skatole in the fat.

Abstract: Embodiments of the present invention provide a pharmaceutical intervention in the neonatal to infantile ruminants that inhibits the activation of the HPG axis, growth of the testis and inhibits testicular production of testosterone, which prevent the development of aggressive behavior in the maturing males and the presence of male-specific odor in the meat. The invention comprises treatment with an estrogen or a combination of an estrogen and an androgen in the newborn males using extended drug delivery methods, with a defined duration of no more than 1-4 months or infantile period of growth, for the purpose of inhibiting the production of testosterone and the accumulation of male-specific odor. The drug delivery component may consist of biocompatible-/biodegradable polymers in the form of pellets, microspheres, or gels, or in solvents or solutions (hereafter, drug complex).

Abstract: Embodiments of the present invention provide a pharmaceutical intervention in neonatal to infantile pigs, ruminants, and other livestock that inhibits the activation of the HPG axis, growth of the gonads and inhibits gonadal production of sex hormones, which will prevent the estrous cycle until the age at slaughter. The invention comprises treatment with estrogen or estrogen in combination with androgen in the newborn to infantile females using extended drug delivery methods, with a defined duration of between 1-4 months or infantile period of growth, for the purpose of the prevention of the estrous cycle in female production animals. The drug delivery component may consist of biocompatible polymers in the form of pellets, microspheres, or gels, or in solvents or solutions (hereafter, drug complex).

Abstract: Methods and apparatus for encrypting and decrypting data for wearable devices that are not based on authentication techniques, such as login/password or handshaking, are provided. A computing device receives a message. The message includes encrypted data and a cryptographic reference. The encrypted data includes physiological data of a wearer of the wearable device. The cryptographic reference includes a reference to a first cryptographic technique. The computing device determines the first cryptographic technique based on the reference to the first cryptographic technique. The computing device determines a cryptographic key. The computing device decrypts the encrypted data using the first cryptographic technique and the cryptographic key to obtain decrypted data. The computing device stores the decrypted data.

Abstract: The present invention relates to compositions comprising and methods of producing genetically engineered bacteriophages, bacteriophage-like particles and non-replicating transduction particles (NRTPs) that contain non-native tail fibers that display altered host specificity and/or reactivity. The present invention also relates to methods of using these bacteriophages and NRTPs for the development of novel diagnostics, therapeutics and/or research reagents for bacteria-related diseases.

Abstract: Methods for polishing semiconductor substrates are disclosed. The methods may involve alternating a first and second polishing slurry during polishing. The first and second slurries each contain silica particles with the silica particles of the first slurry containing more silica than the particles of the second slurry. By alternating between first and second polishing slurries, the polishing method may improve wafer flatness.

Abstract: A system can display content generated from one type of machine-generated data to a user via a graphical user interface. Based on an interaction with the machine-generated data, the system can determine an entity identifier associated with the machine-generated data and determine an entity type for the entity identifier. The system can map the entity type to one or more content generators associated with the entity type and communicate the entity identifier to the identified content generators. The content generators can determine if they have content associated with the machine-generated data. The system can generate and display a link to the related content via a graphical user interface.

Abstract: The present invention relates to compositions comprising and methods of producing genetically engineered bacteriophages, bacteriophage-like particles and non-replicating transduction particles (NRTPs) that contain non-native tail fibers that display altered host specificity and/or reactivity. The present invention also relates to methods of using these bacteriophages and NRTPs for the development of novel diagnostics, therapeutics and/or research reagents for bacteria-related diseases.

Abstract: The present disclosure, in some embodiments, relates to an integrated chip processing tool. The integrated chip processing tool includes a first transfer module and a second transfer module. The first transfer module has a first robotic arm disposed within a housing. The first transfer module is configured to receive a single and unitary first die tray configured to hold a plurality of integrated chip (IC) die and to concurrently transfer all of the plurality of IC die held by the single and unitary first die tray to a single and unitary die boat. The second transfer module has an additional robotic arm disposed within the housing and configured to concurrently transfer all of the plurality of IC die from the single and unitary die boat to a single and unitary second die tray.

Abstract: The present invention relates to compositions and methods for the use of polymerase chain reaction (PCR) as a reporter assay for rapid and simultaneous bacterial identification and phenotype testing for antimicrobial susceptibility (AST). The current invention uses a strategy that has shown the ability for multiplexing and for handling polymicrobial samples for antimicrobial susceptibility testing.

Abstract: The present invention relates to compositions and methods for the use of polymerase chain reaction (PCR) as a reporter assay for rapid and simultaneous bacterial identification and phenotype testing for antimicrobial susceptibility (AST). The current invention uses a strategy that has shown the ability for multiplexing and for handling polymicrobial samples for antimicrobial susceptibility testing.

Abstract: A system can display content generated from one type of machine-generated data to a user via a graphical user interface. Based on an interaction with the machine-generated data, the system can determine an entity identifier associated with the machine-generated data and determine an entity type for the entity identifier. The system can map the entity type to one or more content generators associated with the entity type and communicate the entity identifier to the identified content generators. The content generators can determine if they have content associated with the machine-generated data. The system can generate and display a link to the related content via a graphical user interface.

Abstract: A system can display content generated from one type of machine-generated data to a user via a graphical user interface. Based on an interaction with the machine-generated data, the system can determine an entity identifier associated with the machine-generated data and determine an entity type for the entity identifier. The system can map the entity type to one or more content generators associated with the entity type and communicate the entity identifier to the identified content generators. The content generators can determine if they have content associated with the machine-generated data. The system can generate and display a link to the related content via a graphical user interface.

Abstract: The present invention relates to compositions and methods for the use of polymerase chain reaction (PCR) as a reporter assay for rapid and simultaneous bacterial identification and phenotype testing for antimicrobial susceptibility (AST). The current invention uses a strategy that has shown the ability for multiplexing and for handling polymicrobial samples for antimicrobial susceptibility testing.